קלופידקסל 75 - Clopidexcel 75
×××× ×× ×× × ×ספ×× ×©× ×§××פ×××§×¡× - Clopidexcel
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | B01AC Platelet aggregation inhibitors excluding heparin | |||||
|---|---|---|---|---|---|---|
| ×ר××× ×¤×¢×× (ATC5) | Â
| |||||
| צ×רת ××ª× | פ××× - PER OS | |||||
| צ×רת ××× ×× | ×××××ת ×צ×פ×ת פ×××, FILM COATED TABLETS ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | |||||
| ×ת×××× | Prevention of atherotrobmotic eventsClopidogrel is indicated in :⢠Adult Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.⢠Adult Patients suffering from Acute Coronary Syndrome- Non-ST segment elevation acute coronary syndrome (unstable angina/non-Q-wave myocardial infarction (MI)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). - ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapyPrevention of atherotrobmotic and thromboembolic events in atrial fibrillation: In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with Vitamin K antagonists (VKA) Anti-Thrombin or Anti Factor Xa, and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.
| |||||
× ×ª×× × ×¡× [ ×צ×× ]
| ||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
××× ×¢××× ×ר×פ×
| |||||
| ×¢××× ×צר×× | Â
|
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ק××פ×××§×¡× 75 ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | DEXCEL LTD, ISRAEL |
| ×©× ××¢× ×ר×ש×× | DEXCEL PHARMA TECHNOLOGIES LTD |
| ר×ש××× | ת×ר×× ××ש×: 01/2011. ר×ש××× ×ת×ר××: 08/2015 |
| ת×ר×× ×¢×××× ××ר×× | 14/05/19 |